FDA Brief

Warning letters Food

FDA warning letter to

iwi

High riskIssued Nov 14, 2022Posted Nov 17, 2022Center for Food Safety and Applied Nutrition (CFSAN)

FDA warned iwi that its iwi Cholesterol supplement is an unapproved new drug because website claims say it lowers cholesterol.

What happened

FDA reviewed iwi's website in October 2022, along with Facebook, Amazon and Walmart pages that direct consumers to buy iwi Cholesterol. FDA found claims such as “clinically shown to decrease cholesterol” and “lowering bad cholesterol,” which show the supplement is intended to treat or prevent disease. FDA says the product is therefore an unapproved new drug and is misbranded because it lacks adequate directions for use.

What FDA found

  1. The website, Facebook, Amazon and Walmart claims show iwi Cholesterol is intended to treat or prevent disease, so FDA treats it as a drug.

    section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)]
  2. The product is an unapproved new drug because it is not generally recognized as safe and effective for the claimed cholesterol and heart uses and has no FDA approval.

    section 201(p) of the Act [21 U.S.C. 321(p)]; sections 301(d) and 505(a) [21 U.S.C. 331(d), 355(a)]
  3. The product is misbranded because it lacks adequate directions for a layperson to use it safely for its intended purposes.

    section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]; 21 CFR 201.5
  4. Selling the misbranded drug in interstate commerce violates the Act.

    section 301(a) of the Act [21 U.S.C. 331(a)]

What FDA wants

Within 15 working days of receipt, notify FDA in writing of the specific steps taken to address the violations, including steps to prevent recurrence and copies of related documentation. If correction cannot be completed in that time, state the reason and when it will be completed; if iwi believes the product is not in violation, include its reasoning and supporting information.

Who should pay attention

  • Dietary supplement brands making cholesterol or heart-health claims
  • Retailers and online marketplaces selling supplement listings
  • Marketing and regulatory teams reviewing disease claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk